Looking for:
Clotrimazole and betamethasone contraindications - |
- Clotrimazole and betamethasone contraindications
Read and follow these instructions carefully. Ask your doctor if you have any questions. This medicine is for use on the skin only. Do not get it into your eyes, nose, mouth, or vagina, or apply it on your face or under your arms. To help clear up your skin infection completely, it is very important that you keep using this medicine for the full time of treatment, even if your symptoms begin to clear up after a few days.
Since fungus or yeast infections may be very slow to clear up, you may have to continue using this medicine every day for several weeks or more. If you stop using this medicine too soon, your symptoms may return. Do not miss any doses. The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine.
If your dose is different, do not change it unless your doctor tells you to do so. The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing. There is a problem with information submitted for this request. Sign up for free, and stay up to date on research advancements, health tips and current health topics, like COVID, plus expertise on managing health. To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you.
If you are a Mayo Clinic patient, this could include protected health information. Reassess the diagnosis if there is no clinical improvement after 2 weeks. Special Precautions. Not recommended for the treatment of diaper dermatitis. Pregnancy and lactation. Adverse Reactions. Significant: Reversible hypothalamic-pituitary-adrenal HPA axis suppression, visual disturbances e.
General disorders and administration site conditions: Oedema. Infections and infestations: Secondary infection. Nervous system disorders: Paraesthesia.
Skin and subcutaneous tissue disorders: Burning and stinging sensation, irritation, maculopapular rash, skin dryness, erythema, pruritus, skin peeling, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, skin atrophy, striae, miliaria. Patient Counseling Information. Do not use occlusive dressing. Avoid contact with eyes or mouth. Monitoring Parameters. Monitor for signs and symptoms of HPA axis suppression or adrenal insufficiency, signs of skin infection or ocular changes.
Lab Interference. Betamethasone: May suppress the flare and wheal reactions to skin test antigens. Description: Betamethasone is a corticosteroid that has anti-inflammatory, antipruritic, and vasoconstrictive actions. It induces the phospholipase A 2 inhibitory proteins lipocortins and sequentially inhibits the release of arachidonic acid, thereby depressing the formation, release, and activity of endogenous chemical mediators of inflammation e.
Clotrimazole is an imidazole antifungal agent. It alters cell wall permeability by binding to phospholipids in the fungal cell membrane which leads to loss of essential intracellular elements, thereby inhibiting fungal growth.
Pharmacokinetics: Absorption: Betamethasone: Absorbed percutaneously. Clotrimazole: Penetrates the epidermis. Distribution: Betamethasone: Crosses the placenta.
Metabolism: Betamethasone: Metabolised in the liver. Clotrimazole: Metabolised in the liver to inactive compounds. Excretion: Betamethasone: Via urine and bile. Clotrimazole: Via faeces and urine. Chemical Structure.
PubChem Database. MIMS Class. Topical Anti-Infectives with Corticosteroids. Betamethasone Topical. Lexicomp Online. Hudson, Ohio.
❾-50%}- Betamethasone + Clotrimazole: Indication, Dosage, Side Effect, Precaution | MIMS Malaysia
Gently massage sufficient Clotrimazole and Betamethasone Dipropionate Cream or Lotion into the affected and surrounding skin areas twice a day, in the morning and evening. Treatment for 2 weeks on the groin or on the body, and for 4 weeks on the feet is recommended.
The use of Clotrimazole and Betamethasone Dipropionate Cream or Lotion for longer than 4 weeks is not recommended for any condition. Prolonged use of Clotrimazole and Betamethasone Dipropionate Cream or Lotion may lead to unwanted side effects. The following side effects have been reported with topical corticosteroid medications: itching, irritation, dryness, infection of the hair follicles, increased hair, acne, fragile blood vessels, spider veins, sensitization local reactions upon repeated application of product , change in skin color, allergic skin reaction, skin thinning, and stretch marks.
In children, reported adverse events for Clotrimazole and Betamethasone Dipropionate Cream include slower growth, Cushing's syndrome a type of hormone imbalance that can be very serious , and local skin reactions, including thinning skin and stretch marks. Hormone imbalance adrenal suppression was demonstrated in clinical studies in children. Can Clotrimazole and Betamethasone Dipropionate Cream or Lotion be used if I am pregnant or plan to become pregnant or if I am nursing?
Before using Clotrimazole and Betamethasone Dipropionate Cream or Lotion, tell your doctor if you are pregnant or plan to become pregnant. Also, tell your doctor if you are nursing. Shake well before using Clotrimazole and Betamethasone Dipropionate Lotion.
This medicine was prescribed for your particular condition. Only use Clotrimazole and Betamethasone Dipropionate Cream or Lotion to treat the condition for which your doctor has prescribed. It may harm them. This leaflet summarizes the most important information about Clotrimazole and Betamethasone Dipropionate Cream and Lotion. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about Clotrimazole and Betamethasone Dipropionate Cream and Lotion that is written for health professionals.
DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed. DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. Due to inconsistencies between the drug labels on DailyMed and the pill images provided by RxImage , we no longer display the RxImage pill images associated with drug labels. We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels.
View Package Photos. Drug Label Info. This is a repackaged label. Clotrimazole and Betamethasone Dipropionate Clotrimazole and Betamethasone Dipropionate Cream, USP has been shown to be at least as effective as clotrimazole alone in a different cream vehicle.
Clotrimazole Skin penetration and systemic absorption of clotrimazole following topical application of Clotrimazole and Betamethasone Dipropionate Cream or Lotion have not been studied. Microbiology Mechanism of Action Clotrimazole is an imidazole antifungal agent.
Activity In Vitro In vitro, clotrimazole has been shown to have activity against many dermatophytes, but the clinical significance of this information is unknown. Drug Resistance Strains of dermatophytes having a natural resistance to clotrimazole have not been reported. Betamethasone Dipropionate Betamethasone dipropionate, a corticosteroid, has been shown to have topical dermatologic and systemic pharmacologic and metabolic effects characteristic of this class of drugs.
Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. General Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment.
Information for Patients Patients using Clotrimazole and Betamethasone Dipropionate Cream or Lotion should receive the following information and instructions: The medication is to be used as directed by the physician and is not recommended for use longer than the prescribed time period.
It is for external use only. Avoid contact with the eyes, the mouth, or intravaginally. This medication is to be used for the full prescribed treatment time, even though the symptoms may have improved. Notify the physician if there is no improvement after 1 week of treatment for tinea cruris or tinea corporis, or after 2 weeks for tinea pedis. This medication should only be used for the disorder for which it was prescribed. Other corticosteroid-containing products should not be used with Clotrimazole and Betamethasone Dipropionate Cream or Lotion without first talking with your physician.
Any signs of local adverse reactions should be reported to your physician. Patients should avoid sources of infection or reinfection. When using Clotrimazole and Betamethasone Dipropionate Cream or Lotion in the groin area, patients should use the medication for 2 weeks only, and apply the cream or lotion sparingly. Patients should wear loose-fitting clothing. Notify the physician if the condition persists after 2 weeks. The safety of Clotrimazole and Betamethasone Dipropionate Cream or Lotion has not been demonstrated in the treatment of diaper dermatitis.
Adverse events consistent with corticosteroid use have been observed in patients treated with Clotrimazole and Betamethasone Dipropionate Cream, USP for diaper dermatitis. Infections and infestations: Secondary infection.
Nervous system disorders: Paraesthesia. Skin and subcutaneous tissue disorders: Burning and stinging sensation, irritation, maculopapular rash, skin dryness, erythema, pruritus, skin peeling, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, skin atrophy, striae, miliaria. Patient Counseling Information. Do not use occlusive dressing. Avoid contact with eyes or mouth.
Monitoring Parameters. Monitor for signs and symptoms of HPA axis suppression or adrenal insufficiency, signs of skin infection or ocular changes. Lab Interference. Betamethasone: May suppress the flare and wheal reactions to skin test antigens. Description: Betamethasone is a corticosteroid that has anti-inflammatory, antipruritic, and vasoconstrictive actions.
It induces the phospholipase A 2 inhibitory proteins lipocortins and sequentially inhibits the release of arachidonic acid, thereby depressing the formation, release, and activity of endogenous chemical mediators of inflammation e. Clotrimazole is an imidazole antifungal agent. It alters cell wall permeability by binding to phospholipids in the fungal cell membrane which leads to loss of essential intracellular elements, thereby inhibiting fungal growth. Pharmacokinetics: Absorption: Betamethasone: Absorbed percutaneously.
Clotrimazole: Penetrates the epidermis. Distribution: Betamethasone: Crosses the placenta. All rights reserved.
Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes. Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.
This site complies with the HONcode standard for trustworthy health information: verify here. This content does not have an English version. This content does not have an Arabic version. See more conditions. Products and services. If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices.
You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail. You'll soon start receiving the latest Mayo Clinic health information you requested in your inbox. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
If you are a consumer or patient please visit this version. Clotrimazole and Betamethasone Dipropionate Cream and Lotion contain combinations of clotrimazole, a synthetic antifungal agent, and betamethasone dipropionate, a synthetic corticosteroid, for dermatologic use. Clotrimazole is an odorless, white crystalline powder, insoluble in water and soluble in ethanol.
Betamethasone dipropionate is a white to creamy white, odorless crystalline powder, insoluble in water. Clotrimazole and betamethasone dipropionate cream is smooth, uniform and white to off-white in color. Each gram of Clotrimazole and Betamethasone Dipropionate Lotion contains Clotrimazole and Betamethasone Dipropionate Cream, USP has been shown to be at least as effective as clotrimazole alone in a different cream vehicle.
No comparative studies have been conducted with Clotrimazole and Betamethasone Dipropionate Lotion and clotrimazole alone. Use of corticosteroids in the treatment of a fungal infection may lead to suppression of host inflammation leading to worsening or decreased cure rate. Skin penetration and systemic absorption of clotrimazole following topical application of Clotrimazole and Betamethasone Dipropionate Cream or Lotion have not been studied.
Only 0. Clotrimazole is an imidazole antifungal agent. The methylsterols may affect the electron transport system, thereby inhibiting growth of fungi.
In vitro, clotrimazole has been shown to have activity against many dermatophytes, but the clinical significance of this information is unknown. Strains of dermatophytes having a natural resistance to clotrimazole have not been reported. Resistance to azoles including clotrimazole has been reported in some Candida species. No single-step or multiple-step resistance to clotrimazole has developed during successive passages of Trichophyton mentagrophytes.
Betamethasone dipropionate, a corticosteroid, has been shown to have topical dermatologic and systemic pharmacologic and metabolic effects characteristic of this class of drugs. The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids.
Once absorbed through the skin, the pharmacokinetics of topical corticosteroids are similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile. Therefore, use is not recommended in patients less than 17 years of age, in diaper dermatitis, and under occlusion.
In clinical studies of tinea corporis, tinea cruris, and tinea pedis, patients treated with Clotrimazole and Betamethasone Dipropionate Cream, USP showed a better clinical response at the first return visit than patients treated with clotrimazole cream. In tinea corporis and tinea cruris, the patient returned 3 to 5 days after starting treatment, and in tinea pedis, after 1 week. Mycological cure rates observed in patients treated with Clotrimazole and Betamethasone Dipropionate Cream, USP were as good as or better than in those patients treated with clotrimazole cream.
In these same clinical studies, patients treated with Clotrimazole and Betamethasone Dipropionate Cream, USP showed better clinical responses and mycological cure rates when compared with patients treated with betamethasone dipropionate cream.
In the treatment of tinea pedis twice daily for 4 weeks, Clotrimazole and Betamethasone Dipropionate Lotion was shown to be superior to vehicle in relieving symptoms of erythema, scaling, pruritus, and maceration at week 2.
Clotrimazole and Betamethasone Dipropionate Lotion was also shown to have a superior mycological cure rate compared to vehicle 2 weeks after discontinuation of treatment. It is unclear if the relief of symptoms at 2 weeks in this clinical study with Clotrimazole and Betamethasone Dipropionate Lotion was due to the contribution of betamethasone dipropionate, clotrimazole, or both.
In the treatment of tinea cruris twice daily for 2 weeks, Clotrimazole and Betamethasone Dipropionate Lotion was shown to be superior to vehicle in the relief of symptoms of erythema, scaling, and pruritus after 3 days.
It is unclear if the relief of symptoms after 3 days in this clinical study with Clotrimazole and Betamethasone Dipropionate Lotion was due to the contribution of betamethasone dipropionate, clotrimazole, or both. The comparative efficacy and safety of Clotrimazole and Betamethasone Dipropionate Lotion versus clotrimazole alone in a lotion vehicle have not been studied in the treatment of tinea pedis or tinea cruris or tinea corporis.
The comparative efficacy and safety of Clotrimazole and Betamethasone Dipropionate Lotion and Clotrimazole and Betamethasone Dipropionate Cream have also not been studied. Clotrimazole and Betamethasone Dipropionate Cream and Lotion are indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes and Trichophyton rubrum.
Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of Clotrimazole and Betamethasone Dipropionate Cream or Lotion for the treatment of infections caused by zoophilic dermatophytes e.
Microsporum canis has not been established. Several cases of treatment failure of Clotrimazole and Betamethasone Dipropionate Cream, USP in the treatment of infections caused by Microsporum canis have been reported. Clotrimazole and Betamethasone Dipropionate Cream or Lotion is contraindicated in patients who are sensitive to clotrimazole, betamethasone dipropionate, other corticosteroids or imidazoles, or to any ingredient in these preparations.
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment.
Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Conditions which augment systemic absorption include use over large surface areas, prolonged use, and use under occlusive dressings.
Use of more than one corticosteroid-containing product at the same time may increase total systemic glucocorticoid exposure. Patients applying Clotrimazole and Betamethasone Dipropionate Cream or Lotion to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, morning plasma cortisol, and urinary-free cortisol tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid.
Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur, requiring supplemental systemic corticosteroids. Three of the eight normal subjects on whom Clotrimazole and Betamethasone Dipropionate Cream, USP was applied exhibited low morning plasma cortisol levels during treatment.
One of these subjects had an abnormal Cortrosyn test. The effect on morning plasma cortisol was transient and subjects recovered one week after discontinuing dosing. If irritation develops, Clotrimazole and Betamethasone Dipropionate Cream or Lotion should be discontinued and appropriate therapy instituted. Patients using Clotrimazole and Betamethasone Dipropionate Cream or Lotion should receive the following information and instructions:.
If there is a lack of response to Clotrimazole and Betamethasone Dipropionate Cream or Lotion, appropriate confirmation of the diagnosis, including possible mycological studies, is indicated before instituting another course of therapy.
The following tests may be helpful in evaluating HPA-axis suppression due to the corticosteroid components:. There are no adequate laboratory animal studies with either the combination of clotrimazole and betamethasone dipropionate or with either component individually to evaluate carcinogenesis.
It was positive in the in vitro human lymphocyte chromosome aberration assay, and equivocal in the in vivo mouse bone marrow micronucleus assay.
This pattern of response is similar to that of dexamethasone and hydrocortisone. Reproductive studies with betamethasone dipropionate carried out in rabbits at doses of 1. These doses are approximately 5- and fold the maximum human dose based on body surface areas, respectively.
No adverse effects on the duration of estrous cycle, fertility, or duration of pregnancy were noted. There have been no teratogenic studies performed in animals or humans with the combination of clotrimazole and betamethasone dipropionate. Corticosteroids are generally teratogenic in laboratory animals when administered at relatively low dosage levels. Betamethasone dipropionate has been shown to be teratogenic in rabbits when given by the intramuscular route at doses of 0.
This dose is approximately one-fifth the maximum human dose. The abnormalities observed included umbilical hernias, cephalocele and cleft palates. Betamethasone dipropionate has not been tested for teratogenic potential by the dermal route of administration.
Some corticosteroids have been shown to be teratogenic after dermal application to laboratory animals. There are no adequate and well-controlled studies in pregnant women of the teratogenic effects of topically applied corticosteroids. Therefore, Clotrimazole and Betamethasone Dipropionate Cream or Lotion should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk.
Because many drugs are excreted in human milk, caution should be exercised when Clotrimazole and Betamethasone Dipropionate Cream or Lotion is administered to a nursing woman. Adverse events consistent with corticosteroid use have been observed in patients under 12 years of age treated with Clotrimazole and Betamethasone Dipropionate Cream, USP. In openlabel studies, 17 of 43 In another open-label study, 8 of 17 Because of higher ratio of skin surface area to body mass, pediatric patients under the age of 12 years are at a higher risk with Clotrimazole and Betamethasone Dipropionate Cream or Lotion.
The studies described above suggest that pediatric patients under the age of 17 years may also have this risk. They are at increased risk of developing Cushing's syndrome while on treatment and adrenal insufficiency after withdrawal of treatment.
Hypothalamic-pituitary-adrenal HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation.
Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Clinical studies of Clotrimazole and Betamethasone Dipropionate Cream or Lotion did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Postmarket adverse event reporting for Clotrimazole and Betamethasone Dipropionate Cream in patients aged 65 and above includes reports of skin atrophy and rare reports of skin ulceration. Caution should be exercised with the use of these corticosteroid-containing topical products on thinning skin. Adverse reactions reported for Clotrimazole and Betamethasone Dipropionate Cream in clinical trials were paresthesia in 1.
Adverse reactions reported for Clotrimazole and Betamethasone Dipropionate Lotion in clinical trials were burning and dry skin in 1. The following local adverse reactions have been reported with topical corticosteroids and may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria, capillary fragility ecchymosestelangiectasia, and sensitization local reactions upon repeated application of product.
In the pediatric population, reported adverse events for Clotrimazole and Betamethasone Dipropionate Cream include growth retardation, benign intracranial hypertension, Cushing's syndrome HPA axis suppressionand local cutaneous reactions, including skin atrophy. Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Adverse reactions reported with the use of clotrimazole are as follows: erythema, stinging, blistering, peeling, edema, pruritus, urticaria, and general irritation of the skin. Acute overdosage with topical application of Clotrimazole and Betamethasone Dipropionate Cream or Lotion is unlikely and would not be expected to lead to a life-threatening situation.
Clotrimazole and Betamethasone Dipropionate Cream or Lotion should not be used for longer than the prescribed time period. Gently massage sufficient Clotrimazole and Betamethasone Dipropionate Cream or Lotion into the affected skin areas twice a day, in the morning and evening.
This combination medication is used to treat a variety of inflamed fungal skin infections such as ringworm, athlete's foot, and jock itch. Contraindications. Documented hypersensitivity ; Cautions. Do not use with occlusive dressing; systemic absorptioin of topical corticosteroids may cause. For topical dosage forms (cream or lotion). For tinea cruris and tinea corporis: Adults and children 17 years of age and older—Apply to the. CONTRAINDICATIONS. Clotrimazole and Betamethasone Dipropionate Cream or Lotion is contraindicated in patients who are sensitive to clotrimazole, betamethasone. Please refer to the Malaysia prescribing information. Generic Medicine Info. Indications and Dosage. Topical/Cutaneous Tinea corporis, Tinea cruris. Adult. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur, requiring supplemental systemic corticosteroids. Betamethasone: May suppress the flare and wheal reactions to skin test antigens.This information is not country-specific. Please refer to the Malaysia prescribing information. Indications and Dosage. Max: 45 g per week as cream ; 45 mL per week as lotion.
Reassess the diagnosis if there is no clinical improvement after 1 week. Child: Available preparations: Betamethasone dipropionate 0. Treatment guidelines may vary among individual products or between countries refer to local product-specific recommendations. Adult: Available preparations: Betamethasone dipropionate 0. Reassess the diagnosis if there is no clinical improvement after 2 weeks. Special Precautions. Not recommended for the treatment of diaper dermatitis. Pregnancy and lactation.
Adverse Reactions. Significant: Reversible hypothalamic-pituitary-adrenal HPA axis suppression, visual disturbances e. General disorders and administration site conditions: Oedema. Infections and infestations: Secondary infection. Nervous system disorders: Paraesthesia. Skin and subcutaneous tissue disorders: Burning and stinging sensation, irritation, maculopapular rash, skin dryness, erythema, pruritus, skin peeling, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, skin atrophy, striae, miliaria.
Patient Counseling Information. Do not use occlusive dressing. Avoid contact with eyes or mouth. Monitoring Parameters. Monitor for signs and symptoms of HPA axis suppression or adrenal insufficiency, signs of skin infection or ocular changes.
Lab Interference. Betamethasone: May suppress the flare and wheal reactions to skin test antigens. Description: Betamethasone is a corticosteroid that has anti-inflammatory, antipruritic, and vasoconstrictive actions. It induces the phospholipase A 2 inhibitory proteins lipocortins and sequentially inhibits the release of arachidonic acid, thereby depressing the formation, release, and activity of endogenous chemical mediators of inflammation e.
Clotrimazole is an imidazole antifungal agent. It alters cell wall permeability by binding to phospholipids in the fungal cell membrane which leads to loss of essential intracellular elements, thereby inhibiting fungal growth. Pharmacokinetics: Absorption: Betamethasone: Absorbed percutaneously.
Clotrimazole: Penetrates the epidermis. Distribution: Betamethasone: Crosses the placenta. Metabolism: Betamethasone: Metabolised in the liver. Clotrimazole: Metabolised in the liver to inactive compounds.
Excretion: Betamethasone: Via urine and bile. Clotrimazole: Via faeces and urine. Chemical Structure. PubChem Database. MIMS Class. Topical Anti-Infectives with Corticosteroids. Betamethasone Topical. Lexicomp Online. Hudson, Ohio. Betamethasone and Clotrimazole. Buckingham R ed. Martindale: The Complete Drug Reference [online]. Pharmaceutical Press. Source: U. National Library of Medicine.
Joint Formulary Committee. Betamethasone with Clotrimazole. British National Formulary [online]. Lotriderm 0. Therapeutic uses, prescribing information and product availability may vary between countries. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise.
All rights reserved. Powered by MIMS. Available Brands. Creobic Double Action. Related Diseases. Register or sign in to continue. Continue with Google. Sign Up. Already a member? Sign in. Special Precautions Not recommended for the treatment of diaper dermatitis. Patient Counseling Information Do not use occlusive dressing. Monitoring Parameters Monitor for signs and symptoms of HPA axis suppression or adrenal insufficiency, signs of skin infection or ocular changes.
Lab Interference Betamethasone: May suppress the flare and wheal reactions to skin test antigens. Action Description: Betamethasone is a corticosteroid that has anti-inflammatory, antipruritic, and vasoconstrictive actions.
References Anon.
Comments
Post a Comment